David G. P. Allan
Mr. Allan has served as a director since June 2003. Since February 1998, Mr. Allan has been Chairman & CEO of YM BioSciences, Inc., a publicly traded, Toronto-based life sciences company focused on cancer therapy. From March 1992 to January 1998, Mr. Allan was the Executive Director of Yorkton Securities Inc., an investment banking firm. Prior to March 1992, he served as a Director of the investment banking firm Loewen, Ondatjee McCutcheon, Inc. Mr. Allan is a director of DiaMedica, Inc., a publicly traded life sciences company focused on diabetes therapy.
> Return to top.
Barry R. Frankel
Mr. Frankel has served as a director since June 2003. In March 1993, Mr. Frankel began serving as Managing Partner of The Frankel Group, a life sciences management consulting firm. From October 1982 to February 1993, Mr. Frankel was President of SJ Weinstein Associates, a healthcare marketing and communications firm. From October 1977 to September 1982, he worked in various senior marketing and strategy positions at Pfizer Inc. Prior to September 1977, Mr. Frankel was a life science research analyst for Citibank Investment Management Group.
> Return to top.
Richard L. Franklin, MD
See Management section for profile.
> Return to top.
Joerg Gruber
Mr. Gruber has served as a director since April 2007. He co-founded Clubb Capital Limited, a London-based corporate finance and venture capital firm with a focus on healthcare, in 1995 and has acted as its Chairman since 1999. From April 1990 to June 1995, Mr. Gruber worked as an independent venture capital consultant. From November 1988 to March 1990, he served as Director of Fixed Income Sales for Shearson Lehman. From March 1985 to October 1988, Mr. Gruber was an institutional sales executive in the Fixed Income Division of Goldman Sachs in London. Mr. Gruber is currently a director of Scandinavian Minerals Limited, a mining company listed on the Toronto Stock Exchange.
> Return to top.
Robert P. Hickey
See Management section for profile.
> Return to top.
Walter R. Maupay, Jr.
Mr. Maupay has served as a director of the Company since July 1996. At the time of his retirement in 1995, Mr. Maupay was a group executive with Bristol-Myers Squibb and president of Calgon Vestal Laboratories. From May 1988 to January 1995, he was president of Calgon Vestal Laboratories, a division of Merck & Co., Inc. From 1984 to 1988, Mr. Maupay served as vice president of Calgon Vestal Laboratories. Mr. Maupay is currently a director of the following publicly traded companies: Kinsey Nash Corporation and Cubist Pharmaceuticals, Inc.
> Return to top.